Publication | Open Access
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
41
Citations
0
References
2016
Year
Phase Ia AtezolizumabMedicineImmunologyPathologyImmune Checkpoint InhibitorPredictive Biomarkers ResultsCancer TreatmentOncologyRadiation OncologyLung CancerClinical Activity
No additional data available for this publication yet. Check back later!